Anemia - J&J loses injunction against Amgen
Saturday, December 2nd, 2006J&J loses injunction against Amgen
Johnson & Johnson has lost its injunction to prevent Amgen providing sales discounts on its top-selling drug Aranesp for anemia.
Source: www.pharmaceutical-business-review.com
Cancer Survivors: Watch Weight, Eat Right, Exercise
Getting to a healthy weight, exercising, and eating lots of fruits and vegetables are just as important for cancer survivors as for people who’ve never had the disease, according to a new guide released by the American Cancer Society.
Source: news.yahoo.com
Courts rejects J&J request for Amgen injunction
BOSTON (MarketWatch) — A New Jersey federal court has rejected Johnson & Johnson’s request for a preliminary injunction against Amgen’s current marketing practices for its blockbuster anemia drug Aranesp, the companies confirmed Wednesday.
Source: www.marketwatch.com
Cyclacel Reports Interim Phase I Data for Sapacitabine in Patients with Advanced Leukemias or Myelodysplastic Syndromes
SHORT HILLS, N.J.—-Cyclacel Pharmaceuticals, Inc. announced today interim results from a Phase I pharmacologic trial of sapacitabine , a novel orally-available nucleoside analog, in patients with advanced leukemias or myelodysplastic syndromes .
Source: biz.yahoo.com
Dealing With Celiac Disease
About 2 million Americans are affected by celiac disease, which makes them unable to tolerate gluten, found in wheat rye and barley. Dr. Emily Senay gives tips on how to find out if you have it and how to deal with it if you do.
Source: www.cbsnews.com